News

August 20, 2018August 20, 2018

Patients’ Stem Cells a Potential New Cell Model for Alport Research, Study Suggests

News

Using induced pluripotent stem cells may help researchers identify the underlying mechanisms of Alport syndrome, according to a new study from Monash University in Austrialia. Researchers developed podocyte-like cells ... Read more

August 13, 2018August 13, 2018

Alport Syndrome and Its Challenges Focus of Early August Meeting with FDA

News

The National Kidney Foundation (NKF) recently held a patient-focused drug development meeting concerning Alport syndrome (AS) with the U.S. Food and Drug Administration (FDA). This meeting was conducted in conjunction ... Read more

August 6, 2018August 6, 2018

Recognition of Inheritance Patterns in XLAS Critical for Proper Diagnosis, Care, Case Report Shows

News

Genetic evaluation of direct family members of Alport syndrome patients is an important step to better understanding the underlying features of the disease, as well as to provide proper ... Read more

July 30, 2018July 30, 2018

Phase 2 Trial Data Show Bardoxolone’s Potential to Reverse Kidney Damage in Alport Syndrome

News

One year of treatment with Reata Pharmaceuticals’ bardoxolone methyl can reverse the damaging effects of Alport syndrome, promoting the recovery of kidney function, according to data from a Phase ... Read more

July 23, 2018July 23, 2018

Anonymous $10K Grant Will Provide Surrogacy for Alport Syndrome Patient

News

An anonymous donor’s $10,000 gift to Path2Parenthood will help a woman with Alport syndrome as she and her husband expand their family through surrogacy. The donation from a person ... Read more

July 16, 2018July 16, 2018

Urinary EGF Levels Could Help Predict Alport Syndrome Progression in Children, Study Suggests

News

Measuring epidermal growth factor (EGF) in the urine, in addition to other standard biomarkers, could help predict a decline in kidney function in children with Alport syndrome, researchers suggested. ... Read more

July 9, 2018July 9, 2018

Regulus Pauses Clinical Program of RG-012 as Treatment for Alport Syndrome

News

Regulus Therapeutics has suspended recruitment activities for the RG-012 clinical program in patients with Alport syndrome. This decision was one of the strategic updates and corporate restructuring measures that the ... Read more

July 2, 2018July 9, 2018

COL4A5 Gene Abnormalities May Help Predict Renal Prognosis of XLAS Patients, Study Suggests

News

Mutations in the COL4A5 gene that lead to the production of shorter versions of the encoded protein are linked to a more severe form of Alport syndrome than other ... Read more

June 25, 2018June 25, 2018

Small Molecule Seen to Slow Alport’s Progression in Mouse Model of Disease

News

A small-inhibitor molecule targeting a protein called lysyl oxidase like-2 or LOXL2 was seen to lessen renal scarring and improve the workings of the kidney in a mouse model ... Read more

June 18, 2018June 18, 2018

EU Grants Bardoxolone Orphan Drug Status as Potential Alport Therapy, Phase 3 Trial Enrolling

News

The European Commission (EC) has granted orphan drug status to bardoxolone methyl (bardoxolone)as a possible treatment for Alport syndrome, the therapy’s developer, Reata Pharmaceuticals, announced. Its effectiveness and safety are ... Read more